Prostate cancer treatment with targeted therapy

Targeted drugs are designed to affect certain substances in cancer cells: an excess of specific proteins and compounds or changes in genes absent in normal tissues. Targeted therapy is selected individually, and tumor cells must have particular mutations for its effectiveness. In prostate cancer, a BRCA1/2 mutation may be detected. Its presence means a violation of one of the ways to restore the genetic material of cells, which contributes to the appearance of a tumor. In prostate cancer treatment, particular medications are used, so-called PARP inhibitors. These drugs do not allow damaged DNA to be restored in tumor cells, which leads to their death. The technique can be an independent therapy, but it is most effective with a complex effect on the affected cells. Targeted drugs are injected using droppers with a specific frequency. The introduction of the drug does not take much time. As a rule, it lasts no more than 2 hours.